Cargando…
Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome
Wolfram syndrome (WS) is a rare autosomal recessive disorder caused by mutations in the WFS1 (Wolframin1) gene. The syndrome first manifests as diabetes mellitus, followed by optic nerve atrophy, deafness, and neurodegeneration. The underlying mechanism is believed to be a dysregulation of endoplasm...
Autores principales: | Toots, Maarja, Seppa, Kadri, Jagomäe, Toomas, Koppel, Tuuliki, Pallase, Maia, Heinla, Indrek, Terasmaa, Anton, Plaas, Mario, Vasar, Eero |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033861/ https://www.ncbi.nlm.nih.gov/pubmed/29976929 http://dx.doi.org/10.1038/s41598-018-28314-z |
Ejemplares similares
-
GLP-1 receptor agonist liraglutide has a neuroprotective effect on an aged rat model of Wolfram syndrome
por: Seppa, Kadri, et al.
Publicado: (2019) -
Wfs1- deficient rats develop primary symptoms of Wolfram syndrome: insulin-dependent diabetes, optic nerve atrophy and medullary degeneration
por: Plaas, Mario, et al.
Publicado: (2017) -
Liraglutide, 7,8-DHF and their co-treatment prevents loss of vision and cognitive decline in a Wolfram syndrome rat model
por: Seppa, Kadri, et al.
Publicado: (2021) -
Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype
por: Jagomäe, Toomas, et al.
Publicado: (2021) -
The Expression of RAAS Key Receptors, Agtr2 and Bdkrb1, Is Downregulated at an Early Stage in a Rat Model of Wolfram Syndrome
por: Punapart, Marite, et al.
Publicado: (2021)